Georgia Clinical & Translational Science Alliance

Research Resources
Research Resources
Translating new discoveries to advance health from bench to bedside to community
View Research Resources
Biostatistics, Epidemiology & Research Design
Clinical Research Centers
Collaboration & Team Science
Commercialization
Informatics
Integrating Special Populations
Recruitment
Regulatory Support & Ethics
Research Navigation
Education & Training
Education & Training
Training the next generation of clinical and translational investigators
View Education & Training
Bench2Market Series Talks
Capstone Design
Certificate Program in Translational Science
Clinical Research Professional Courses
eMPACT Career Advancement
Introduction to Clinical & Translational Research
K-Club
KL2
Master of Science in Clinical Research
TL1
Community
Community
Engaging the community in clinical research efforts
View Community
Community Engagement
Community Engagement Forum
Community Funding
Partners
Partner Database
ResearchMatch
Funding
Funding
Funding opportunities for developing the best approaches and methodologies to address complex translational and clinical research problems
View Funding
BizGrants
Community Funding
Pilot Grants
About
About
The institutions of the Georgia Clinical & Translational Science Alliance leverage their complementary strengths to accelerate clinical & translational education, research, & community engagement to impact health.
View About
What We Do
Leadership
News and Events
Evaluating Impact
Contact Us
Submit a Request
Submit a Request
Submit a Request
Request the types of assistance you need for your project
View Submit a Request
Submit a Request
Ask a Navigator

Immune Modulator Drugs Improved Survival for People Hospitalized with COVID-19

Jun 9, 2022

COVID-19 molecules — Image Credit: Fernando Da Cunha/Science Photo Library

Preliminary results from ACTIV-1 Immune Modulator clinical trial show immune modulator drugs, infliximab and abatacept, substantially improved clinical status and reduced deaths in adults hospitalized with COVID-19. NIH launched this trial to evaluate safety and efficacy of three immune modulator drugs. The trial was coordinated and overseen by NCATS. NCATS’ CTSA Program and Trial Innovation Network played a key role in enrolling participants.